A groundbreaking study has revealed that weight loss jabs, specifically semaglutide, can significantly reduce alcohol consumption among individuals with alcohol use disorder. The research, conducted in Denmark, demonstrated that weekly injections of semaglutide—marketed as Wegovy for weight loss and Ozempic for type 2 diabetes—cut the number of heavy drinking days per month by more than two-thirds in obese participants seeking treatment for alcohol addiction.
Study Details and Findings
The trial involved 108 obese participants with alcohol use disorder. Over six months, those receiving semaglutide experienced a reduction in heavy drinking days from an average of 17 per month to roughly five. In contrast, the placebo group saw a decrease to nine days. Participants also reported fewer alcohol cravings and lower overall alcohol consumption.
Lead investigator Professor Anders Fink-Jensen commented: "The results suggest that semaglutide not only affects appetite but also influences the biological mechanisms underlying addiction. This opens the door to complementing existing treatments for alcohol use disorder with a GLP-1 receptor-targeted approach."
How Semaglutide Works
Semaglutide mimics the glucagon-like peptide 1 (GLP-1) hormone, which regulates hunger and slows digestion, making users feel full sooner. Originally developed for type 2 diabetes, these GLP-1 agonists also lower blood sugar levels. Previous research has indicated that such drugs may reduce reward processes linked to food intake and decrease harmful inflammation in the body.
First author Dr. Mette Kruse Klausen added: "This is a patient group with a high disease burden and a substantial risk of both physical and mental complications. Reducing the most harmful drinking patterns could make a meaningful difference for patients."
Broader Implications and Considerations
Approximately 2.4 million Britons currently use weekly weight loss injections, with most obtaining them through private prescriptions. While effective, semaglutide can cause side effects such as nausea, leading some users to discontinue treatment. Authorised sellers must provide monitoring and counselling to support diet and lifestyle changes for sustained weight loss.
Without these changes, users may regain weight within a year after stopping the drugs. Additionally, the jabs can lead to loss of muscle and bone density, which is not recovered. Despite these challenges, the potential for treating alcohol use disorder offers a new avenue for addiction therapy.
